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ABSTRACT
Background: Pasteurella multocida is a commensal organism found in the saliva and oropharynx of
domestic animals. It causes a variety ofhuman infections ranging from cellulitis to bacteremia and
sepsis. The severity of infection is somewhat related to the immunocompetency of the infected host.
An immunocompromised host is more likely to suffer a disseminated infection as a result of contact
with this organism than an immunocompetent host. This case report and review of the literature
are presented to further evaluate the types ofinfections caused by this organism in oncology patients.
Case: A 54-year-old woman with epithelial ovarian cancer and a chemotherapy-induced nadir
of her WBC count developed P. multocida bacteremia after she incurred a scratch from her pet
cat. She was treated with ceftazidime and then penicillinG with prompt resolution ofthe bacteremia.
Conclusion: This paper summarizes an infectious complication that is likely to become more
common as chemotherapy-induced neutropenia and pet ownership in the elderly become common
coincidences. As such, oncologists and infectious disease physicians should keep this organism in
mind when selecting antibiotics to treat the febrile, nadiring cancer patient who has known pet
contact. (C) 1996 Wiley-Liss, Inc.
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asteure//a multocida is a gram-negative coccoba-
cillus that exists as a commensal organism in the
gastrointestinal and respiratory tracts of domestic
animals. It can be isolated from the secretions of
70-90% of cats l’z and 50-66% of dogs. 3’4 Human
infections most often result from cat bites, cat
scratches, or dog bites, However, other routes of
infection have been described: direct contamination
of a wound with animal saliva; a pulmonary infec-
tion from the aerosolized secretions of a cat; pneu-
monia caused by direct extension from respiratory
colonization with this organism in a pet owner;
and chorioamnionitis caused by ascending infection
from vaginal colonization with this organism in an
animal handler,
P. multocida may cause a wide spectrum of infec-
tions, Soft-tissue infections resulting from animal
bites are the most common. Less frequent, but more
severe, infections are bone and joint infections;
respiratory infections including bronchitis, pneu-
monia, and empyema; bacteremia and endocardi-
tis;
t-t4 central nervous system infections such as
meningitis, abscesses, and subdural empyema;s
subacute bacterial peritonitis;
16 perinatal infections
including chorioamnionitis and neonatal sepsis;6’8,7
and ocular infections ranging from corneal ulcers to
endophthalmitis,
Severe infections caused by this organism are
more likely to occur in patients who are immuno-
compromised or have chronic underlying medical
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disorders. The most common chronic medical disor-
der associated with P. multocida infections is liver
cirrhosis. 5’1z’13’16 P. multocida infection has also been
reported in association with the following medical
conditions: a variety of malignancies, renal fail-
ure, systemic lupus erythematosis, chronic lung
disease, acquired immunodeficiency syndrome
(AIDS), diabetes, paraplegia, rheumatoid arthritis,
and the relatively immunocompromised state of
pregnancy.5,6,1,
8
We report a case of P. multocida bacteremia in a
patient with ovarian cancer who became neutro-
penic after treatment with chemotherapy. Although
a small number of patients with malignancies and
P. multocida bacteremia have been reported, we are
unaware of cases directly associated with ovarian
carcinoma or chemotherapy-induced neutropenia.
CASE REPORT
A 54-year-old white nulligravida was in good health
until 1993 when she noted the gradual onset of
abdominal distension. A pelvic mass was noted on
pelvic examination and confirmed by a pelvic ultra-
sound. She underwent a total abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, omentec-
tomy, pelvic lymphadenectomy, appendectomy,
and optimal debulking. A pathological examination
revealed a stage IIIC, grade 2-3, serous cystadeno-
carcinoma of the ovary. She subsequently received
4 of 6 cycles of cyclophosphamide (500 mg/m) and
carboplatin (350 mg/mz) at 4-week intervals.
Nine days after her 4th cycle of chemotherapy,
she developed a severe generalized headache, sore
throat, and experienced an episode of emesis. Dur-
ing the night, she experienced rigors with a temper-
ature of38.3C. Her malaise worsened the following
morning, and she noted a tender left anterior cervi-
cal lymph node. She took acetominophen (625 mg)
and sought medical care.
She appeared pale and ill. Her temperature was
37.5C, heart rate 80, blood pressure 100/60, and
respiratory rate 20/min. She had a tender, slightly
enlarged left anterior cervical lymph node. There
was no pharyngeal erythema or exudate. She had
a few old cat scratches on her back and a recent
noninflamed scratch on her right wrist. Two porta-
caths present subcutaneously in her upper right
chest wall were not inflamed. The remainder of her
examination was unremarkable. Her WBC count
was 6,200 mm3; the absolute neutrophil count
(ANC) was 5,800 including 74% mature neutrophils
and 20% band forms. She was admitted to the hospi-
tal because of her fever, malaise, and ill appearance.
Blood cultures were obtained from her portacaths
as well as from a peripheral vein. A throat culture
and urine culture were also obtained. Her tempera-
ture increased to 39.1C. Two more sets of blood
cultures were obtained and ceftazidime, 2 g q 8 h,
was administered. She defervesced rapidly on anti-
biotics and felt dramatically better 24 h later. Within
24 h, the blood cultures yielded a g-negative cocco-
bacillus which was identified as P. multocida. The
organism was sensitive to ampicillin, cefazolin, gen-
tamicin, mezlocillin, and ciprofloxacin. The antibi-
otic therapy was changed to penicillin G, 4 million
units q 6 h, after a 3rd set of blood cultures was
obtained from each of her portacaths. By the 2nd
hospital day, she developed leukopenia with aWBC
count of 2,500 mm (ANC of 1,575 mm3). Granulo-
cyte Colony Stimulating Factor (G-CSF) was be-
gun. She was discharged home on the 4th hospital
day when her 3rd set of blood cultures remained
negative at 48 h. She completed 7 days of intrave-
nous (IV) penicillin G and 7 days of oral amoxicillin.
After P. mu/tocida was identified, additional in-
formation regarding animal contact was elicited
from the patient. She had 3 cats and 2 dogs at home.
She was advised to declaw the cats and to avoid
direct contact with pet saliva during any periods
of neutropenia.
DISCUSSION
P. multocida is a microorganism encountered fre-
quently in everyday life, especially among pet own-
ers. In the moderately immunocompromised pa-
tient, this encounter can result in a serious and
sometimes fatal infection. The medical condition
most frequently associated with serious P. multocida
infections is hepatic cirrhosis. P. multocida bacter-
emia in patients with cirrhosis results in mortality
rates of 31% and 37%, as reported by Raffi et al.1
and Weber et al., respectively.
Oncology patients also have increased suscepti-
bility to infections with this organism, probably as
a result of immunosuppression caused by their ma-
lignancies and by chemotherapy and radiation ther-
apy. At least 19 cases of cancer patients with infec-
tions caused by P. multocida have been reported
(Table 1). The reported cases include patients with
both hematologic malignancies and various solid
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TABLE I. Clinical features and outcome of oncology patients with P. multocida infections
Case Years Other medical Antibiotic
no. of age Tumor type problem Infection treatment
Animal
exposure Outcome
69 Lung carcinoma
2 74 Bladder-transitional
cell carcinoma
3 70 Macroglobulinemia
(CT)
4 tt 81 Chronic
lymphocytic
leukemia
5 18 Hepatocellular
carcinoma
63 65 Metastatic breast
carcinoma (CT)
7s 62 Metastatic
squamous cell
carcinoma of the
tongue (CT, RT)
89 56 Rectosigmoid
adenocarcinoma
919 72
1019 41
II 19 60
129 79
Biliary
adenocarcinoma
(RT)
Acute monoblastic
leukemia (CT,
N)
Metastatic breast
adenocarcinoma
1319 60 Lung carcinoma
14 t9 57 Acute
myelogenous
leukemia (CT,
N)
1519 75 Ameloblastoma
169 64 Metastatic cervical
carcinoma
1719 65 Gingival carcinoma
1819 55 Soft palate
epidermoid
carcinoma
19 54 Ovarian carcinoma
(CT, N)
COPD Pneumonia Cefazolin,
tobramycin,
cephalexin
Bacteremia, Gentamicin,
cellulitis ampicillin,
penicillin
Bacteremia Ampicillin,
amikacin
Bacteremia, Penicillin,
cellulitis cephalothin,
gentamicin
Biliary cirrhosis Bacteremia Ampicillin
Bacteremia Penicillin
Alcoholism Subdural Ampicillin
empyema
Congestive heart Recurrent Cephalothin,
failure bacteremia, gentamicin,
perirectal clindamycin
abscess
Liver transplant Recurrent
immunosuppression bacteremia,
subhepatic
abscess
Thigh abscess
Arm ulcer
infection
Emphysema Sputum
colonization
Pulmonary fibrosis, Sputum
bronchiectasis colonization
Pulmonary embolism, Sputum
systemic colonization
aspergillosis
Congestive heart
failure, bronchitis
Cirrhosis
Pneumonia
Vaginal
infection
Sputum
colonization
Pneumonia
Pet dog R
Cat and dog R
scratches
and bites
Pet dog R
Cat bite R
Pet dog D
Pet cat R
Pet dog R
Pet dog D
Bacteremia Ceftazidime, Cat scratch, R
penicillin G pet cats
and dogs
aCT chemotherapy; COPD chronic obstructive pulmonary disease; RT radiation therapy; N neutropenia; R recovered; D died;
not available.
bSuperscript numbers refer to reference citations.
cPresent study.
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tumors. Eight of 19 (42%) of the oncology patients
had bacteremia caused by P. multocida. Four of
these 8 patients also had simultaneous localized
infections such as soft-tissue cellulitis. Three of
8 (37%) patients with bacteremia died from their
infections. Two of the 3 deaths occurred in patients
with underlying liver disease.
Pulmonary infections were the 2nd most com-
mon infection, occurring in 7 of 19 (37%) patients; 3
patients had pneumonia and 4 patients had sputum
colonized with P. multocida. Five of the 7 (71%)
patients with pulmonary infections caused by P.
multocida had associated underlying pulmonary dis-
orders. The other infections reported in oncology
patients included abscess formation (N 3), ulcer
infection (N 1), and a vaginal infection (N 1).
Nine of the 19 (47%) patients had known animal
exposures. Only 3 (33%) of these exposures were
traumatic. This rate oftraumatic exposure to animals
is similar to the 41% reported by Raffi et al. 11 in their
review of P. multocida sepsis. Thus, other portals of
entry of this microorganism may exist in the cancer
population, e.g., aerosolized animal secretions, vagi-
nal or pulmonary colonization, or contamination of
skin wounds or ulcers with animal saliva.
There are only 3 reported cases of P. multocida
infections occurring in cancer patients with neutro-
penia as a result of chemotherapy. Two patients
had localized infections (cases 10 and 14, Table 1).
The current case report is the only case known to
the authors of P. multocida bacteremia occurring
during a chemotherapy-induced nadir (case 19, Ta-
ble 1).
Pasteurella is usually exceedingly sensitive to an-
tibiotic treatment. The drug of choice is penicillin
G, although penicillin-resistant strains have been
described.5’1’1’z Alternative drugs that are usually
effective include ampicillin, carbenicillin, mezlocil-
lin, parenteral cephalosporins, tetracycline, and
chloramphenicol. The organism is variably sensitive
to the aminoglycosides and erythromycin. P. multo-
cida is universally resistant to vancomycin and clin-
damycin.
Empiric broad-spectrum antibiotic coverage of
the febrile and neutropenic cancer patient has been
a mainstay of therapy in oncology. Since the 1980s,
the number ofthese patients with documented sites
of infection has decreased from 75% to 30-40%,
probably attributable to prompt initiation ofempiric
antibiotic therapy in this setting. Additionally, the
types of pathogens predominantly causing infec-
tions in this group of patients have shifted from
gram-negative bacteria (Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa) to gram-
positive organisms (coagulase-negative staphylo-
cocci, Staphylococcus aureus, and streptococci) as well
as fungal, viral, and parasitic pathogens,
el The initial
therapy usually consists of a 3rd-generation cepha-
losporin, such as ceftazidime, or imipenim alone or
an extended-spectrum penicillin with an aminogly-
coside or 3rd-generation cephalosporin. All of these
empiric regimens would be efficacious in initially
treating infections caused by P. multocida but should
be modified once the antibiotic sensitivities of the
organism are known for the reasons previously dis-
cussed. Vancomycin is generally reserved for those
febrile neutropenic patients in whom a specific
pathogen is isolated that justifies its use. Modifica-
tions in the initial antibiotic regimen should be
made promptly in response to changes in the clinical
picture or changes in the microbiologic profile.
The addition of hematopoietic cytokines such
as granulocyte (G-) and granulocyte-macrophage
(GM-) colony-stimulating factors (CSF) to the
treatment regimen of the oncology patient with fe-
ver and neutropenia results in a shortening of the
duration of absolute neutropenia. Because of the
expense of these cytokines, the guidelines for their
use made by our institutional pharmacy designate
specific groups of patients: patients needing rescue
from severe (ANC of <500 or < 1,000 and dropping)
drug-induced or infection-induced bone marrow
failure (with or without fever); patients having re-
ceived a previous course of the same chemothera-
peutic regimen that resulted in profound (ANC of
<500) neutropenia or neutropenic infections; and
patients undergoing bone-marrow or peripheral
stem-cell transplantation. These cytokines are dis-
continued when the ANC is >2,000 or the WBC
is >5,000 following the expected chemotherapy-
induced neutrophil nadir.
In summary, P. multocida should be considered
a potential infectious agent causing bacteremia in
oncology patients who are febrile or neutropenic,
particularly if they have histories of exposure to
domestic animals or underlying medical disorders
such as cirrhosis or chronic pulmonary disease. Al-
though the benefits of animal companionship out-
weigh the risk of infection to the oncology patient
with a pet, we feel that physicians should keep in
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mind the potential animal exposures in this group
of patients and readily provide advice for safe prac-
tices of pet ownership, especially during periods of
chemotherapy-induced neutropenia.
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